Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab Effect on Insulin Secretion
NCT04314167Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Jul 2020
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of evolocumab in hypercholesterolemia, sponsored by University Hospital Tübingen. Primary endpoint: Change in insulin secretion at 12 weeks. Started Jul 2020; status: terminated.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04314167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314167.